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A THOUSAND TINY PIECES: THE FEDERAL CIRCUIT‘S FRACTURED MYRIAD RULING, LESSONS TO 
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The Supreme Court granted, vacated, and remanded the infamous Myriad gene isolation 
patentability case to the Court of Appeals for the Federal Circuit (CAFC) in light of the recent 
Prometheus decision, which held 9-0 that a certain diagnostic method was invalid subject matter 
because it was an abstract idea merely modified by other obvious steps.  This Essay argues that 
Myriad should be affirmed again by the Federal Circuit, particularly in light of Prometheus, in 
order to inject certainty, clarity, and consistency into the § 101 patentable subject matter 
jurisprudence.   
 
 
Then beneath the earth those hidden blessings for man, bronze, iron, silver and gold—who can 
claim to have discovered before me?  No one, I am sure, who wants to speak to the purpose.  In 







On July 29, 2011, the Court of Appeals for the Federal Circuit handed down the long-
awaited decision in Association of Molecular Pathology v. U.S. Patent and Trademark Office 
(AMP v. USPTO or Myriad I)
2
 upholding the patentability of claims on isolated human genes
3
 in 
                                                 
1
 AESCHYLUS, PROMETHEUS BOUND (GREEK TRAGEDY IN NEW TRANSLATIONS) ll. 498–505 
(James Scully & C. John Herington trans., University Oxford Press 1975) (c. 415 B.C.E.).   
* Summer Associate, Finnegan, Henderson, Farabow, Garrett, & Dunner LLP, 2012 (expected); 
Patent Examiner, United States Patent and Trademark Office, 2007–2012.  J.D., American 
University Washington College of Law (WCL), 2013 (expected); M.A., Print Journalism, 
University of Southern California, 2006; B.S.E., Biomedical Engineering, Tulane University, 
2004.  Mr. Stroud is the Senior Symposium Editor of the Administrative Law Review, the Senior 
Symposium Chair for the Intellectual Property Brief (IP Brief), and the Executive Tournament 
Director of the Moot Court Honor Society.  He is also a Dean‘s Fellow to Professors Jonas 
Anderson and Andrew Popper and is the founder of the Court of Apppeals for the Federal Circuit 




a 2–1 decision that has provoked a petition to rehear the case en banc,
4
 which was denied.
5
  
Subsequently, a Supreme Court petition for certiorari was filed,
6
 which the high court recently 
granted, vacated, and remanded (GVRed) in Association of Molecular Pathology v. U.S. Patent 
and Trademark Office (Myriad II)
7
 in light of their recent decision in Mayo Collaborative 
Services v. Prometheus Laboratories, Inc. (Prometheus).
8
 
After the Federal Circuit‘s initial decision, the genomic testing startup companies 
breathed a collective (if temporary) sigh of relief.  That is, until the Supreme Court issued its 
                                                                                                                                                             
Michael Ruggiero and Corrine Parver, without whose teachings this would not have been 
written.  
2. Ass‘n of Molecular Pathology v. U.S. Patent & Trademark Office (Myriad I), 653 F.3d 1329 
(Fed. Cir. 2011), cert. granted, vacated, and remanded sub nom. Ass‘n of Molecular Pathology 
v. Myriad Genetics, Inc. (Myriad II), No. 11–725, WL 986819 (U.S. Mar. 26, 2012)(remanding 
to the Federal Circuit for further consideration in light of Mayo Collaborative Services v. 
Prometheus Laboratories, Inc., 132 S. Ct. 1289 (2012)). 
3. Compare James J. Mullen, III & Mary Prendergast, Federal Circuit Decision in Myriad 
Genetics Confirms that Isolated Human DNA Molecules Are Patentable, MORRISON FOERSTER 
(Aug. 1, 2011), http://www.mofo.com/files/Uploads/Images/110801-DNA-Molecules-
Patentable.pdf (highlighting the case as a win for diagnostic manufacturers interested in isolated 
human genome testing), with Recent Case, Federal Circuit Invalidates Diagnostic Method 
Claims as Drawn to “Abstract Mental Processes.”—Association for Molecular Pathology v. 
U.S. Patent & Trademark Office, 653 F.3d 1329 (Fed. Cir. 2011), 125 HARV. L. REV. 658, 658 
(2011) (arguing the case erroneously invalidated all diagnostic ―method patents‖ under an 
unadvisable ―abstract mental processes‖ standard), and Courtenay Brinckerhoff, Federal Circuit 
Issues Mixed Decision on Myriad Claims, PHARMAPATENTS (July 30, 2011), 
http://www.pharmapatentsblog.com/federal-circuit-decisions/federal-circuit-decides-myriad-oks-
isolated-dna-claims/ (calling the Federal Circuit‘s Myriad I ruling a ―mixed decision‖ and saying 
that ―there is much to be analyzed before the full impact of this decision—and the contours of 
the holdings—will be understood‖). See also Seth R. Ogden, Note, The Federal Circuit’s 
Decision in Myriad: Isolated DNA Molecules Are Patentable Subject Matter, 61 AM. U. L. REV. 
443 (2011).  
4. Petition for Rehearing En Banc, Ass‘n of Molecular Pathology v. U.S. Patent and Trademark 
Office, No. 2010-1406 (Fed. Cir. Aug. 31, 2011). 
5. Denial of Petition for Rehearing En Banc, Ass‘n of Molecular Pathology v. U.S. Patent and 
Trademark Office, No. 2010-1406 (Fed. Cir. Sept. 13, 2011). 
6. See Kevin E. Noonan, AMP v. USPTO: Oral Argument at the Federal Circuit, PATENT DOCS 
(Apr. 7, 2011, 12:00 PM), http://www.patentdocs.org/2011/04/amp-v-uspto-oral-argument-at-
the-federal-circuit.html (―[The Myriad I case] is likely to be subject to en banc review, a petition 
for certiorari to the Supreme Court, or both. The case is far from over.‖). 
7
 See Ass‘n of Molecular Pathology v. U.S. Patent and Trademark Office (Myriad II) No. 11–
725, WL 986819 (U.S. March 26, 2012): ―The petition for a writ of certiorari is granted.  The 
judgment is vacated, and the case is remanded to the United States Court of Appeals for the 
Federal Circuit for further consideration in light of Mayo Collaborative Services v. Prometheus 
Laboratories, Inc., 556 U.S. ___ (2012).‖ 
8. Mayo Collaborative Servs. v. Prometheus Labs., Inc., No. 10–1150 (March 20, 2012) (slip 




recent GVR, thus recreating the original uncertainty surrounding gene patents.  The case is the 
latest chapter in the AMP v. USPTO saga, which has thrown the biotech world into turmoil over 
contentious genetic testing and threatened the future of personalized medicine in America. The 
Federal Circuit was right to rule definitively, and it is unfortunate that the dissenting judge 
divided the opinion and created uncertainty.  The Supreme Court compounded that uncertainty 
when they chose to GVR the case and again create a swirl of confusion where clarity is sorely 
needed.  
In the wake of the Supreme Court‘s recent unanimous invalidation of a diagnostic testing 
patent in Prometheus as unpatentable subject matter,
9
 however, commentators have suggested 
that the Federal Circuit may reverse the panel decision in light of the Supreme Court‘s 
unanimous precedent.
10
  Prometheus indicates that obvious subject matter, coupled with what the 
Court believes are laws of nature, is not patentable under § 101.  Thus, the possibly obvious 
isolation of human genes could be held invalid, as isolation techniques have existed for some 
time.   
Part II of this Article will give a brief synopsis of the procedural and historical 
background of the case and will discuss the importance of the patent claims to the genetic 
diagnostics industry and personalized medicine in general. Part III will analyze the Federal 
Circuit‘s divided opinion; Part IV will discuss Prometheus.  Part IV will attempt to draw 




The Patent and Trademark Clause of the U.S. Constitution grants the federal government 
the ability to grant patent rights,
11
 and those laws have been codified for nearly as long as there 
has been a United States of America.
12
 The statutory subject matter requirement is set forth in 35 
U.S.C. § 101, and reads ―Whoever invents or discovers any new and useful process, machine, 
manufacture, or composition of matter, or any new and useful improvement thereof, may obtain 
                                                 
9
.  Id. at *8 (asking ―do the patent claims add enough to their statements of the correlations to 
allow the processes they describe to qualify as patent-eligible processes that apply natural laws?‖ 
and stating ―We believe that answer is no.‖).  
10
 Dennis Crouch, Mayo v. Prometheus: Natural Process + Known Elements = Normally No 
Patent, PATENTLY-O.COM (May 20, 2012), http://www.patentlyo.com/patent/2012/03/ mayo-v-
prometheus-natural-process-known-elements-normally-no-patent.html: 
 
Following Mayo, the court could logically find that the information in the DNA 
represents a law of nature, that the DNA itself is a natural phenomenon,  that the 
isolation of the DNA simply employs an isolation process already well known and 
expected at the time of the invention, and ultimately that the isolated DNA is 
unpatentable because it effectively claims a law of nature or natural phenomenon. 
  
11. ―To promote the Progress of Science and useful Arts, by securing for limited Times to 
Authors and Inventors the exclusive Right to their respective Writings and Discoveries.‖ U.S. 
CONST. art. I, § 8, cl. 8.  
12. See United States Patent Act, 35 U.S.C. §§ 100–105 (2006) (granting statutory authority to 




a patent therefor, subject to the conditions and requirements of this title.‖
13
 The Courts have 
usually interpreted the clause broadly, subject to a few judicially created exemptions.
14
 
A. Procedural Background 
 
Since the Supreme Court ruled in 1980 in Diamond v. Chakrabarty that bioengineered 
living organisms are patentable subject matter,
15
 the USPTO has generally held that isolated 
human genes—segments of human genes that have been excised, with non-important parts 
spliced out, and then isolated in the laboratory—are patentable,
16
 to the tune of thousands of 
issued patents over the years.
17
 However, the lower district court in AMP v. USPTO invalidated 
patent claims to two controversial isolated genes, the BRCA 1 and 2 genes, which have been 
linked to a higher risk of female patients developing breast cancer.  
The case was a surprise to many
18
 and threw the market for many start-up biotech 
companies into disarray, as a judicial cloud settled over their isolated gene patents.
19
 
Complicating matters further, the Justice Department and the U.S. Solicitor General took an 
interest in the case, and although the Solicitor General of the USPTO generally argues cases in 
front of the Federal Circuit on behalf of the government, instead the Justice Department 




                                                 
13. Id. § 101. 
14. See Ass‘n of Molecular Pathology v. U.S. Patent and Trademark Office (Myriad I), 653 F.3d 
1329, 1348 (Fed. Cir. 2011) (discussing the ―broad, [but] not unlimited‖ nature of § 101).  
15. 447 U.S. 303, 310 (1980) (stating that the ability of man resulted in bacteria with ―markedly 
different characteristics‖ and the ―potential for significant utility‖).  
16. See, e.g., 66 Fed. Reg. 1092, 1093 (Jan. 5, 2001) (formally stating said longstanding policy).  
17. See Ass’n of Molecular Pathology, 653 F.3d at 1355 (―It is estimated that the PTO has issued 
2,645 patents claiming ‗isolated DNA‘ over the past twenty-nine years, and that by 2005, had 
granted 40,000 DNA-related patents covering, in non-native form, twenty percent of the genes in 
the human genome.‖(internal citations omitted)); id. at 1367 (Moore, J., concurring) (―[T]here 
are now thousands of patents with claims to isolated DNA, and some unknown (but certainly 
large) number of patents to purified natural products or fragments thereof.‖). 
18. See, e.g., Robert Carlson, Surprise District Court Ruling Invalidates Myriad Genetics’ BRCA 
Patents, But Appeal Is Pending, BIOTECH. HEALTHCARE (Summer 2010), at 8–9, available at 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2899793/.  
19. Id. (saying that members of the bar were ―surprised‖ and ―dismayed‖ and that it was 
―contrary to . . . Federal Circuit precedent‖).  
20. See Jonathan Stroud, Myriad Madness—How the Department of Justice is Working Counter 
to U.S. Interests, INTELL. PROP. BRIEF (Feb. 22, 2011, 7:00 AM), 
http://www.ipbrief.net/2011/02/22/myriad-madness-%E2%80%93-how-the-department-of-
justice-is-working-counter-to-u-s-interests/ (―This highly unusual request by the Justice 
Department—preempting the Department of Commerce‘s usual role in appellate-level arguments 
for all patent cases—only highlights the deep divisions between the two agency‘s positions.―). 
The Federal Circuit referred to the infighting obliquely:  
Although the PTO did not ―sign‖ the brief and we are left to guess about the status 
of any possible continuing inter-agency disagreements about the issue, the 




B. Personalized Medicine, Diagnostic Companies, and You 
 
Personalized Medicine is the use of an individual‘s characteristics, in particular, their 
genetic information, to target medicines to the individual rather than administer traditional drugs 
in the same form and dose to all patients, in a one-size-fits-all model.
21
 It has been heralded by 
the heads of the FDA and the NIH as the future of medicine,
22
 and involves packaging genetic 
diagnostic testing and targeted medicines together, such as the recently FDA-approved cancer 
treatments crizotinib, and its genetic associated test.
23
 
In 2004, the Food and Drug Administration (FDA) approved a similar drug called 
erlotinib as a second-line defense for a subset of lung cancer patients.
24
 In various clinical tests, 
the drug has produced uneven—but dramatic—results. Some patients had 30% shrinkage of their 
tumors; others had an amazing 99% shrinkage, nearly curing them entirely;
25
 and some had 
almost no shrinkage at all.
26
 This had some calling it a miracle drug,
27
 while others questioned 
                                                                                                                                                             
Executive Branch, so it is fair to assume that the Executive Branch has modified 
its position from the one taken by the PTO in its 2001 guidelines and, informally, 
before that.  
Ass’n of Molecular Pathology, 653 F.3d at 1380–81 (majority opinion). 
21. See generally FRANCIS S. COLLINS, THE LANGUAGE OF LIFE: DNA AND THE REVOLUTION IN 
PERSONALIZED MEDICINE (2010) (discussing the future of genetics and the biotech industry). 
22. See Margaret A. Hamburg & Francis S. Collins, The Path to Personalized Medicine, 363 
NEW ENG. J. MED. 301, 301–04 (2010) (calling for greater collaboration between the Food and 
Drug Administrative (FDA) and the National Institute of Health (NIH)).  
23. Molly Peterson, Pfizer Wins U.S. Approval for Lung Cancer Drug Seen as Filling Lipitor 
Gap, BLOOMBERG NEWS (Aug. 27, 2011), http://www.bloomberg.com/news/2011-08-26/pfizer-
wins-u-s-approval-for-tumor-fighting-medicine-to-treat-lung-cancer.html (reporting that Pfizer 
won approval of the drug, which is targeted to a specific form of lung cancer caused by a gene 
defect, along with the related genetic test approved by Abbott Labs); see also Abbott Says FDA 
Clears Leukemia Genetic Test, YAHOO! NEWS (Aug. 22, 2011), http://news.yahoo.com/abbott-
says-fda-clears-leukemia-genetic-test-154708318.html (citing approval of a similar genetic test 
for leukemia).  
24. Tarceva® Erlotinib Tablets, GENENTECH, 
http://www.gene.com/gene/products/information/oncology/tarceva/ (last visited Mar. 19, 2012) 
(―Tarceva® (erlotinib) is a small molecule human epidermal growth factor type 1/epidermal 
growth factor receptor (HER1/EGFR) inhibitor which demonstrated, in a Phase III clinical trial, 
an increased survival in advanced non-small cell lung cancer (NSCLC) patients.‖). 
25. HOWARD HUGHES MED. INST., GENETIC ACCOMPLICE HELPS SOME LUNG TUMORS EVADE 
TREATMENT (March 23, 2011), available at 
http://www.hhmi.org/news/pdf/sawyers20110323.pdf (―Within weeks, [erlotinib] can shrink 
tumors with a particular mutation to near vanishing. But the drug does not work equally well in 
all patients. For others with the same mutation, the results can be disappointing. Tumors may 
only shrink by 30 percent.‖). 
26. Heidi Ledford, Mutations Block Lung-Cancer Treatment, NATURE (Mar. 23, 2011), 
http://www.nature.com/news/2011/110323/full/news.2011.178.html (―These drugs help most 




the wisdom of approving a costly drug treatment that conveyed to many the false hope of a 
dramatic cure.
28
 Nonetheless, the U.S. manufacturer Genentech has encouraged clinical research, 
and recent results have shown that clinicians can identify smaller and smaller subsets of lung 
cancer patients who will benefit through genetic testing.
29
 
 Recently, the National Comprehensive Cancer Network and the American Society of 
Clinical Oncology (ASCO) recommended lung cancer patients be screened for a specific genetic 
mutation—EGFR—to identify patients most likely to benefit from the drug.
30
 By combining the 
expensive drug with the genetic test, researchers believe patient outcomes can be improved,
31
 
while others who might respond poorly to the medication can be screened out.
32
 It would also 
justify the high cost to the small subset of users who would benefit. Yet it has taken more than 
five years to make even this modest suggestion that targeted testing can improve outcomes. So 
this and similar drugs‘ future effectiveness seems to be pegged to the successful implementation 
of a very specific genetic test.
33
  
                                                                                                                                                             
[a related EGFR-inhibitor], for example. But the rest respond poorly, if at all, and no one knows 
why.‖). 
27. Id. (―For some patients with lung cancer, the drug erlotinib is a near miracle.‖); see also 
Some of Our Survivors Call It the “Miracle Drug,” BONNIE J. ADDARIO LUNG CANCER FOUND., 
http://www.lungcancerfoundation.org/2009/03/19/some-of-our-survivers-call-it-the-
%E2%80%9Cmiracle-drug%E2%80%9D/ (last visited Mar. 19, 2012). 
28. Goran Mijuk & Sten Stovall, Roche's UK Drug Appeal Failure Underscores Problems, DOW 
JONES DEUTSCHLAND (June 29, 2011), http://www.dowjones.de/site/2011/06/roches-uk-drug-
appeal-failure-underscores-problems.html (discussing the manufacturer‘s ―increasing problems 
with government bodies that view its medicines as too expensive‖ and pegging the cost of 
treatment at ―between $30,000 to $60,000 per year‖). 
29. Trever G. Bivona et al., FAS and NF-κB Signalling Modulate Dependence of Lung Cancers 
on Mutant EGFR, 471 NATURE 523, 523–26 (2011) (finding that with Tarceva ―the magnitude of 
tumour regression is variable and transient‖ and that ―this . . . could result from genetic modifiers 
that regulate the degree to which tumour cells are dependent on mutant EGFR‖). 
30. Patrice Wendling, Mutation Testing Guided Erlotinib Prescribing in Lung Cancer, INTERNAL 
MED. NEWS DIGITAL NETWORK (July 11, 2011), 
http://www.internalmedicinenews.com/views/observation-unit/blog/mutation-testing-guided-
erlotinib-prescribing-in-lung-cancer/31b54c31e5.html. 
31. Fred Hirsch, The Role of Genetic Testing in the Prediction of Response to EGFR Inhibitors in 
NSCLC, 28 ONCOGENE S1, S1–S3 (2009) (releasing clinical findings that ―pretreatment detection 
of such markers could facilitate a more personalized and specific approach to therapy, whereby 
the most appropriate and efficacious treatment is selected for a specific subset of patients‖). 
32. See id. (―EGFR mutation testing is ready for routine clinical use and [more targeted] testing 
will soon be ready.‖); cf. Peggy Peck, Tarceva Improves Survival in Subset of Patients with 
Refractory Non-Small Cell Lung Cancer, MEDPAGE TODAY (July 13, 2005), 
http://www.medpagetoday.com/Pulmonology/LungCancer/1353 (―While supporters of Tarceva 
. . . hailed [positive clinical trial results] as a major advance in ‗personalized medicine,‘ the 
absolute numbers were less than overwhelming.‖). 
33. Accord FOOD & DRUG ADMIN., DRAFT GUIDANCE FOR INDUSTRY AND FOOD AND DRUG 
ADMINISTRATION STAFF: IN VITRO COMPANION DIAGNOSTIC DEVICES 5 n.2 (2011) [hereinafter 




Indeed, the NIH recently announced it would, and now has, published a Genetic Testing 
Registry by early 2012, highlighting commercial genetic testing‘s growing importance.
34
 
However, the registry is voluntary,
35
 and there is still a vast need for patent protection, especially 
in light of the FDA‘s confused treatment of genetic tests.  
Over the past fifteen years, the FDA had begun to assert jurisdiction over laboratory 
diagnostic tests (LDTs) and end their long-practiced enforcement discretion.
36
 In July of 2010, 
the FDA held a public meeting announcing its intent to regulate LDTs based on the risks that 
they posed, and stated that guidance would follow.
37
 Then on July 11, 2011 the FDA issued draft 
guidance on what they termed ―in vitro companion diagnostic devices‖ (IVCDDs).
38
  
In it, the FDA would require that the innovator seek FDA approval for new medical 
products (drugs and biologics) under either § 505 of the Federal Food, Drug, and Cosmetic Act 
(FDCA) (drugs)
39
 or § 351 of the Public Health Service Act (PHSA) (biologics),
40
 while the 
innovator must seek contemporaneous approval for the IVCDD under § 510(k) of the Medical 
Device Amendments
41
 to the FDCA.
42
 Effectively, it would assert jurisdiction over any new 
laboratory tests that it are ―essential for the safe and effective use of a corresponding therapeutic 
product.‖
43
 It also seems to require FDA approval for such tests as full IVCDDs, subject to 
                                                                                                                                                             
http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocu
ments/UCM262327.pdf (using Herceptin and the associated test as another example of a 
treatment combination which is only useful for metastatic breast cancer and gastric cancer if the 
patient has the HER-2 genetic marker, which the test reveals).  
34. Genetic Testing Registry, NAT‘L CTR. FOR BIOTECHNOLOGY INFO., 
http://www.ncbi.nlm.nih.gov/gtr/ (last visited Jan. 20, 2012) (―Once operational, GTR will 
provide access to information about genetic tests for inherited and somatic genetic variations, 
including newer types of tests such as arrays and multiplex panels.‖). 
35. Id. (―GTR information about tests primarily will be based on voluntary data submissions by 
test developers and manufacturers.‖). 
36. See, e.g., In Vitro Diagnostic Products For Human Use, 21 C.F.R. pt. 809 (2012); SEC‘Y‘S 
ADVISORY COMM. ON GENETICS, HEALTH, AND SOC‘Y (SACGHS), U.S. SYSTEM OF OVERSIGHT 
OF GENETIC TESTING: A RESPONSE TO THE CHARGE OF THE SECRETARY OF HEALTH AND HUMAN 
SERVICES (2008), http://oba.od.nih.gov/oba/SACGHS/reports/SACGHS_oversight_report.pdf 
(recommending greater FDA oversight of laboratory diagnostic tests (LDTs) consistent with in 
vitro diagnostics (IVDs)). 
37. FDA/CDRH Public Meeting, Oversight of Laboratory Developed Tests (LDTs) (July 19–20, 
2010), available at 
http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm212830.htm. 
38. DRAFT GUIDANCE, supra note 33, at 3, 7.  
39. Federal Food, Drug, and Cosmetic Act, Pub. L. No. 75-717, ch. 675, § 505, 52 Stat. 1040, 
1055 (codified as amended in scattered sections of 21 U.S.C.).  
40. Public Health Service Act, Pub. L. No. 78-410, ch. 373, 58 Stat. 682 (codified as amended at 
42 U.S.C. §§ 262–300jj, 351 (2006 & Supp. II 2006)).  
41. Pub. L. No. 94-295, 90 Stat. 539 (codified as amended in scattered sections of 21 U.S.C.). 
42. DRAFT GUIDANCE, supra note 33, at 7.  








This would ostensibly prevent drug companies from seeking approval for drugs like 
crizotinib or erlotinib without also approving and commercializing the much-needed test and 
relying instead on variable LDTs nationwide. It also serves to expand the FDA‘s authority over 
such devices and would affect drug approvals: For instance, an expensive medicine with a small 
targeted population could possibly fail approval as not being ―effective‖ enough to be generally 
prescribed, unless it was also coupled with the test, which the FDA would, under this guidance, 
require. Lastly, it begins the slow transition to a regulatory framework that considers IVDs an 
essential part of medical treatment. There is also a companion legislative push to regulate by 
statute the devices under a separate pathway at the FDA.
45
 This would lower the cost of 
premarket approval and allow smaller companies to get their commercialized diagnostic tests to 
market.  
However, until the Congress or the FDA acts to streamline the approval process, 
currently the only readily available path to commercialization for small companies is the patent 
process. Companies seeking to commercialize research and development—particularly 
university spinouts and start-up companies—need a fast and effective way to protect their 
research and commercialize their genetic tests, and isolated gene patents have been the primary 
vehicle to do so, particularly for companies like Myriad that do not have the resources of a Pfizer 
or an Abbott Labs to undergo the expensive and time-consuming FDA approval process (as it 
now stands). Thus, the importance of the USPTO v. AMP decision for that industry cannot be 
overstated: In this context, it is an all-or-nothing affair. These companies need these patents to 
survive and continue to innovate, unless and until Congress or the FDA reform to the point 
where these products can be approved cheaply. 
 
C. Myriad Possible Interpretations 
 
                                                 
44. See id. at 8–9.  
45. Advocates of FDA enforcement authority over LDTs and industry representatives seeking a 
clear pathway to approval for more targeted medicines in the development pipeline have begun 
to lobby Congress to expand the regulatory authority of the FDA to include all commercially 
available laboratory tests of any targeted therapeutic significance. See Scott Gottlieb, Will 
Regulation Thwart the Personalization of Medicine?, HEALTH POL‘Y OUTLOOK 3 (Am. Enter. 
Inst. for Pub. Policy Research, Wash., D.C.), Oct. 2010, at 7, 
http://www.aei.org/files/2010/10/22/2010-10-No-3-g.pdf (advocating for a legislative solution to 
the regulatory problem). The easiest vehicle to amend the law would be the reauthorization bill 
of the Prescription Drug User Fee Act, a widely popular bill that is up for reauthorization in 
2012. See id. at 7 (―The way to change LDT regulation may be the reauthorization of the 
Medical Device User Fee and Modernization Act next year, rather than the FDA‘s internal policy 
process. Legislation is likely to get coupled to the act that would give the FDA new authority 
over LDTs.‖). The draft legislation getting the most attention—that is under development by 
Senator Orrin Hatch‘s office—is the Better Evaluation and Treatment Through Essential 
Regulatory Reform for Patient Care (BETTER Patient Care) Act of 2011. SENATE LEGISLATIVE 




The instant cases, Myriad I & II, pits concerned doctors and women‘s health groups 
against the company that isolated the gene and developed and patented the genetic test.
46
 They 
rests largely on two very distinct ways of seeing the science behind isolating the human genome. 
The first could be called the ―informational‖ view, and is the argument that won the day in the 
lower court—that the human genome represents information and sequences that occur naturally, 
and thus cannot be patented. The second can be called the ―chemical‖ or ―mechanical‖ view, and 
it posits that the isolated molecules—which have been chemically cleaved, separated, and do not 
occur in this chemically differing state in nature—are ―markedly different‖ under the Chakabarty 




III. THE FEDERAL CIRCUIT‘S SPLIT DECISION 
 
The Attorney General‘s office argued for the former in this case, positing a ―magic 
microscope‖ test in oral argument, where if one were to magnify the human genome, one could 
see the sequence as claimed in the patent.
48
  
In the majority opinion, Judge Lourie flatly rejected that test,
49
 and adopted the 
―chemical‖ view outlined above.
50
 The majority found that the chemical cleaving of the bonds 
that connect all human genomes produced a markedly different chemical structure than the one 
found in nature, and thus the resulting invention was patentable.
51
 Arguing against the dissent, 
the majority clearly found the informational view lacking, making a clear distinction between 
claims over structure and claims over function.
52
 Further, the majority stressed the ―utility‖ of the 
invention, and the ―markedly different‖ or ―distinctive‖ characteristics.
53
  
In a remarkably well-written concurring opinion, Judge Moore said that, at least with 
regards to a certain set of broad claims, it was a much closer question, but that the economic 
reliance interests and the long-settled expectations of the biotechnology industry tipped the 
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This is a pragmatic argument that takes into account the large number of property rights 
that the Court would be strip from inventors and former applicants, many of whom have been 
relying on their isolated gene patents for decades. Yet the bulk of both opinions rest on the hard 
science—the chemistry of chemical bonds—complete with charts and diagrams, and resists 
devolving into sentimental policy judgments. At the end of the day, § 101 is not the avenue to 
invalidate these patents; Congress is. 
In one of the more memorable lines of the case, the majority seemed to rebuke the lower 
court‘s lengthy opinion, urging deference to Congress and endorsing judicial minimalism: 






On March 20, 2012, the Supreme Court complicated matters when it unanimously held in 
Prometheus that a diagnostic method patent was invalid under § 101 because it ―set forth mere 
laws of nature‖—relationships between blood-borne metabolites and the appropriate dosage of a 
dangerous drug—rather than a patentable diagnostic process.
56
 It held that diagnostic patents that 
apply so-called natural laws using known processes are invalid, and it held that the underlying 
mathematical relationship between metabolite levels of the blood and the drug thiopurine was an 
immutable law of nature.
57
   
Thus, the Supreme Court endorsed a ―law-of-nature-plus-obviousness‖ methodology for 
analyzing unpatentable subject matter under § 101, whereby any mathematical equation or 
natural relationship that is applied using an already-known methodology is invalid under § 101.
58
  
The Court noted that many argued in the case that ―a principle of law denying patent 
coverage here will interfere significantly with the ability of medical researchers to make valuable 
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discoveries, particularly in the area of diagnostic research,‖
59
 but found equally compelling the 
counter-argument brought by, among others, the Association of Molecular Pathology, the 
petitioner in Myriad I & II.
60
 They argued is that if patent protection is allowed over the body‘s 
natural response to drugs, then ―the result will be a vast thicket of exclusive rights over the use of 




Justice Breyer was seemingly nervous about ruling in such a way as to protect the 
medical diagnostic industry that might have produced unforeseen results in other fields of 
technology,
62
 for instance, in internet patents.  Frustratingly, the Court sidestepped the issue, 
stating, ―we must recognize the role of Congress in crafting more finely tailored rules where 
necessary‖ and ―we need not determine here whether, from a policy perspective, increased 
protection from discoveries of diagnostic laws of nature is desirable.‖ 
63
 Indeed, the Court chose 
not to address the issue at all, much to the chagrin of the Author and the entire diagnostic testing 
community.  
Thus, it is an open question whether human genomic sequences might rise to the level of 
natural laws isolated via a known means of isolation, or whether the Federal Circuit may hold 
that the isolation of specific genes is a non-obvious means of harnessing and testing for the gene 
and uphold Myriad II based on the analysis put forth in Prometheus.    
 
V. INFERENCES AND ARGUMENTS 
 
The Federal Circuit‘s majority opinion in Myriad I argued persuasively, adopted the 
chemical view, and was the correct position, and Judge Moore‘s concurrence eloquently 
bolstered the Court‘s position, while both the majority and the concurring opinion weakened the 
dissent‘s reasoning, and both make a persuasive case based on sound scientific and economic 
principles.  The validity and strength of the ruling, however, has been cast into doubt by the 
binding precedent of Prometheus. Yet to understand the lingering doubts, the emotional 
resonance of the dissent, and the uncertainty cast on the case by the Supreme Court‘s GVR, one 
must look to the underlying issue in the case.  
The unspoken view at the heart of the conflict, one that does not appeal to the scientist or 
even to legal reason but rather to baser emotions, is the basic ―my body, my property‖ view. This 
view essentially conflates the genetic information that is common to most human beings—and 
hence the potential unlocked when its sequence is discovered—with a person‘s own individual 
DNA. The logic is simple—the DNA is mine. No one else can own it. It conjures up images of 
human organ trafficking and reminds us of dystopian science fiction plotlines about 
commoditized body parts, and it ostensibly raises issues about personal privacy and bodily 
autonomy. Like the magic microscope test or the dissent‘s leaf test, it has ―curb appeal‖ and ―a 
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 but it ultimately oversimplifies and perhaps misunderstands the issues in 
the case in a play to emotions.  
It would be intellectually disingenuous to say that the true issue is over personal 
autonomy. The problem is that Myriad did not seek to buy or sell any individual‘s particular 
genome, or genetic material, or even to prevent them from analyzing it—they sought to exclude 
others from making or using only the test for analyzing it that they innovated. Beyond the 
emotional appeal, we must understand the pragmatic effects of such a limited ruling. Without 
allowing such patents to stand, the court would doom the nascent personalized medicine 
movement that has given us erlotinib and crizotinib, and it would render targeted care more 
difficult to innovate and thus provide. Complex companion tests, IVCDDs, and LDTs would not 
be commercially viable at all without such patent protection and a strong FDA approval pipeline, 
and companies would be forced to abandon promising treatments to seek greener pasteurizations, 
so to speak.  
The true underlying issue we must keep in mind is not the existence of the test Myriad 
developed—it is the cost. All agree that the test itself is highly beneficial and may save lives; 
why else would so many people and groups be interested in the test in the first place? The 
question is whether the patent system is the appropriate vehicle for protecting genetic diagnostic 
testing.  
In response, you do not throw the baby out with the bathwater. One may not always like 
the cost of prescription medicines, but sick patients are still better off when beneficial drugs and 





 or too over-enforced,
67
 but allowing the Courts to alter precedent and simply 
invalidate the patents entirely in one broad stroke is not the solution. 
Nor should the Prometheus decision alter this ruling.  The Myriad company invested a 
large amount of time and money locating, identifying, and isolating the genes in question, and 
then recreating the unique methodology required to isolate these particular genes on a 
commercial scale. Thus, even if isolating other genes is a known method of testing for them, the 
isolation of each specific gene requires a unique chemical methodology that is not generally 
known at the time of patent filing. I believe the Federal Circuit understands the unique nature of 
this chemical process, and will uphold their initial ruling after applying the Prometheus 
framework by determining that the isolation method patented was, in fact, as non-obvious as the 
underlying genes it isolates. At the worst, they should limit the scope of the independent claims 
in light of the specific embodiments outlined in the specification.    
Ultimately, however, the true solution to this problem, as Justice Breyer suggested, is 
through effective legislative and administrative regulation of commercialized diagnostic genetic 
tests, and strong patent protection for isolated gene patents targeting specified genomes. Only 
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then can personalized medicine truly flourish, while still generating jobs, innovation, and 




In conclusion, the majority and concurring opinions in Myriad I provide strong positions 
from which to defend the longstanding practice of allowing patents on chemically isolated 
human genomes, but it remains to be seen whether the Supreme Court‘s Prometheus ruling has 
significantly altered the analysis to the point where they must reverse their ruling. Until then, the 
genomic and diagnostic start-up market will suffer the consequences of that uncertainty.  
Hopefully, the Federal Circuit will quickly issue an opinion reaffirming their previous ruling in 
light of the Prometheus framework, and thus re-inject certainty into a market that is one of 
America‘s brighter spots in terms of innovation, job creation, and economic growth. At the least, 
they can reinforce thousands of preexisting property rights, uphold stare decisis, and leave it to 
Congress to legislate the difficult policy questions.  
